WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc. announces the immediate availability of an expanded Next Generation Sequencing test menu for epilepsy and seizure disorders. The latest epiSEEK® comprehensive panel features exceptional coverage of 489 genes associated with seizure disorders. In addition, Courtagen now offers a new Infancy and Childhood Epilepsy Panel, targeting 70 genes, for physicians requesting a more focused approach.
Help employers find you! Check out all the jobs and post your resume.
